the Efficacy and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells in Lymphoma
Status:
Not yet recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
A single center, non-inferiority, two-way cohort clinical study to evaluate the efficacy and
safety of pegylated recombinant human granulocyte stimulating factor injection in the
mobilization of autologous hematopoietic stem cells in lymphoma.